143782-19-8

Basic information

• Product Name: Benzonitrile, 4-(5-imino-4,4-dimethyl-2-oxo-1-imidazolidinyl)-2-(trifluoromethyl)-
• CAS NO: 143782-19-8
• Molecular Formula: C13H11F3N4O
• Molecular Weight: 296.252
• Mol File: 143782-19-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-(5-imino-4,4-dimethyl-2-oxo-1-imidazolidinyl)-2-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-(5-imino-4,4-dimethyl-2-oxo-1-imidazolidinyl)-2-(trifluoromethyl)-(143782-19-8)
• EPA Substance Registry System: Benzonitrile, 4-(5-imino-4,4-dimethyl-2-oxo-1-imidazolidinyl)-2-(trifluoromethyl)-(143782-19-8)

Safety Data

• Hazardous Substances Data: 143782-19-8(Hazardous Substances Data)

Upstream product

• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 19355-69-2 2-amino-2-cyanopropane 
• 143782-18-7 4-isocyanato-2-(trifluoromethyl)benzonitrile 

Downstream Products

• 1179905-15-7 4-[3-(3,5-bis(trifluoromethyl)benzyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-trifluoromethylbenzonitrile 
• 1179906-32-1 4-(3-benzhydryl-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-trifluoromethyl-benzonitrile 
• 1234780-32-5 N³-(4-bromobenzyl)cyanonilutamide 
• 143782-20-1 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile 

Relevant articles and documents

NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY

Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

Helix 12 directed non-steroidal antiandrogens

Compounds having the structure (or their salts): are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.